TRPV1 and Keratoconjunctivitis sicca: Recently, a novel siRNA for TRPV1, tivanisiran, was designed to reduce ocular pain and was shown to improve ocular hyperemia and tear quality in dry-eye in human and animal models (Moreno-Montañés et al., 2018).